 - Inappropriateness for standard therapy requires a MDS patients: not be a candidate for immediate allogeneic stem cell transplantation, not have a -5q-cytogenetic abnormality unless previously received lenalidomide, and not be an appropriate candidate for a DNA hypomethylating agent b AML patients must be 60 years of age or greater and have one of more of the following documented poor risk factors: ECOG Performance Status 2, 70 years of age or older, unfavorable cytogenetics. 